Study of a Pembrolizumab-based Organ Preservation Strategy for Locally Advanced Larynx Cancers
ACTIVE_NOT_RECRUITING
Status
Conditions
- Squamous Cell Carcinoma of Larynx
Interventions
- DRUG: carboplatin AUC of 6, paclitaxel 175 mg/m2, and pembrolizumab 200 mg, i.v. on day 1, every 21 days for 3 cycles
- RADIATION: Concurrent radio-immunotherapy: radiation therapy given concurrently with pembrolizumab 200 mg i.v. on day 1, every 21 days for 3 cycles.
- DRUG: Consolidation immunotherapy: pembrolizumab 200 mg i.v. on day 1, every 21 days for 11 doses.
Sponsor
Latin American Cooperative Oncology Group
Collaborators